- Advanced search
- Immuno Portal
- Malaria Portal
Molecular properties generated using the CDK
|Compound class||Synthetic organic|
|GSK-J1 is a catalytic site inhibitor that is somewhat selective for the H3K27me3-specific demethylases KDM6A and 6B (a.k.a. UTX and JMJD3 respectively) . The compund has also been shown to inhibit H3K4me3/me2 catalysed by KDM5 enzymes in vitro .
This is a compound from the Structural Genomics Consortium's (SGC) Epigenetics Probes Collection. It reduces lipopolysaccharide-induced proinflammatory cytokine production by human primary macrophages, a process that depends on both JMJD3 and UTX.
|CAS Registry No.||1373422-53-7 (source: Scifinder)|
|GtoPdb PubChem SID||178103606|
|RCSB PDB Ligand||K0I, URY|
|Search Google for chemical match using the InChIKey||AVZCPICCWKMZDT-UHFFFAOYSA-N|
|Search Google for chemicals with the same backbone||AVZCPICCWKMZDT|
|Search UniChem for chemical match using the InChIKey||AVZCPICCWKMZDT-UHFFFAOYSA-N|
|Search UniChem for chemicals with the same backbone||AVZCPICCWKMZDT|
|SynPHARM||83291 (in complex with lysine demethylase 5B)|
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.✖
Cat. No. 4593